share_log

Red Light Holland Initiates Psilocybin Extraction Phase With PharmAla Following Successful Testing and Preparation by CCrest Labs

Red Light Holland Initiates Psilocybin Extraction Phase With PharmAla Following Successful Testing and Preparation by CCrest Labs

繼CCrest Labs成功進行測試和準備之後,Red Light Holland與PharMala啓動了迷幻藥提取階段
newsfile ·  04/23 20:11

Toronto, Ontario--(Newsfile Corp. - April 23, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws, is pleased to announce the successful completion of the initial testing and dehydration of psilocybin truffles at CCrest Laboratories Inc. ("CCrest Labs") in Montreal, Canada. Following this advancement, the dehydrated truffles have been shipped to a lab collaborating with PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) ("PharmAla") for the next phase of extraction and research.

安大略省多倫多--(Newsfile Corp.,2024年4月23日)——Red Light Holland Corp.(CSE:TRIP)(FSE:4YX)(OTCQB:TRUFF)(“Red Light Holland”),一家在北美和歐洲生產、種植和銷售功能性蘑菇和蘑菇家用種植套件以及向荷蘭合法娛樂市場銷售優質迷幻藥松露品牌的公司所有適用的法律,很高興地宣佈,CCrest Laboratories Inc.(“CCrest Labs”)成功完成了對迷幻藥松露的初步測試和脫水工作加拿大蒙特利爾。繼這一進展之後,脫水松露已運往與PharMala Biotech Holdings Inc.(CSE:MDMA)(OTCQB:MDXF)(“PharMala”)合作的實驗室,用於下一階段的提取和研究。

Earlier this month, on April 8th, 2024, Red Light Holland initiated its most substantial shipment yet - 5 kg (5000 grams) of freshly cultivated psilocybin truffles from its farm in the Netherlands to CCrest Labs. This operation conducted by CCrest Labs, after a Health Canada approved psilocybin import permit, is a testament to the rigorous standards and collaborative framework guiding this international venture.

本月早些時候,即2024年4月8日,Red Light Holland開始了迄今爲止最大批量的——從其荷蘭農場向CCrest實驗室運送5千克(5000克)新鮮培育的迷幻藥松露。在獲得加拿大衛生部批准的迷幻藥進口許可證後,由CCrest Labs開展的這項行動證明了指導該國際企業的嚴格標準和合作框架。

CCrest Labs, a cGMP-certified pharmaceutical laboratory, has meticulously completed the dehydration process of the truffles and baseline testing of psychoactive materials (psilocybin & psilocin). The dehydrated truffles have been shipped to PharmAla's development laboratory, Chiral Labs, for extraction. This extraction process is aimed at refining and stabilizing the psilocybin, which is essential for longer shelf life and developing a product intended for clinical research and emerging markets.

CCrest Labs是一家獲得CGMP認證的藥物實驗室,精心完成了松露的脫水過程和精神活性物質(迷幻藥和迷幻藥)的基線測試。脫水松露已運往PharMala的開發實驗室Chiral Labs進行提取。該提取過程旨在提煉和穩定迷幻藥,這對於延長保質期和開發用於臨床研究和新興市場的產品至關重要。

"With the successful testing and preparation of our psilocybin truffles at CCrest Labs, we are now moving into an exciting phase of extraction with PharmAla. This step is critical in our ongoing efforts to unlock the therapeutic potential of psilocybin and develop a commercial-scale process for manufacturing natural-source Active Pharmaceutical Ingredients (API)," said Todd Shapiro, CEO and Director of Red Light Holland.

“隨着我們在CCrest實驗室成功測試和製備我們的迷幻藥松露,我們現在正進入一個令人興奮的PharMala提取階段。紅光荷蘭首席執行官兼董事託德·夏皮羅說,這一步驟對於我們持續努力釋放迷幻藥的治療潛力以及開發生產天然來源活性藥物成分(API)的商業規模工藝至關重要。

Red Light Holland remains dedicated to advancing psychedelic research and is committed to keeping stakeholders informed on the progress and results of this collaboration.

Red Light Holland仍然致力於推進迷幻研究,並致力於讓利益相關者隨時了解此次合作的進展和結果。

About Red Light Holland

荷蘭紅光簡介

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.

Red Light Holland是一家總部位於安大略省的公司,根據所有適用法律,在北美和歐洲從事功能性蘑菇和蘑菇家庭種植套件的生產、種植和銷售,以及向荷蘭合法娛樂市場銷售psilocybin松露的優質品牌。

For additional information on the Company:

有關公司的更多信息:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website:

託德·夏皮羅
首席執行官兼董事
電話:647-643-TRIP (8747)
電子郵件:todd@redlight.co
網站:

About PharmAla

關於 Pharmala

PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla's research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a "regulatory first" organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.

PharMala Biotech Holdings Inc.(CSE:MDMA)(場外交易代碼:MDXXF)是一家生物技術公司,專注於研究、開發和製造包括****在內的MDX類分子。PharMala的創立有兩個重點:緩解全球積壓的仿製藥臨床級****,以便在特定司法管轄區進行臨床試驗和商業銷售,以及開發同類新藥。PharMala是目前唯一一家爲臨床試驗以外的患者治療提供臨床級****的公司。PharMala 的研發部門已經完成了對多個知識產權家族的概念驗證研究,包括其主要候選藥物 ALA-002。PharMala是一個 “監管第一” 組織,成立的原則是,迷幻藥行業的真正成功只能通過與監管機構的良好關係才能實現。

For more information, please contact:

欲了解更多信息,請聯繫:

Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website:

尼古拉斯·卡迪什
首席執行官
PharmaLa 生物科技控股有限公司
電子郵件:press@PharmAla.ca
電話:1-855-444-6362
網站:

About Shaman Pharma Corp.

關於薩滿製藥公司

Shaman Pharma is a federally registered Canadian corporation with the mission to power outstanding psychedelic life science innovation. Accelerating time-to-market through its portfolio of assets, Shaman launches and consolidates revenue-driven pharma-biotech life sciences ventures focused on supplying psychedelic drugs & novel active ingredients.

Shaman Pharma是一家在聯邦政府註冊的加拿大公司,其使命是推動卓越的迷幻生命科學創新。薩滿通過其資產組合加快了上市時間,啓動並整合了以收入爲導向的製藥生物技術生命科學企業,專注於提供迷幻藥物和新型活性成分。

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

關於前瞻性陳述的警示性說明

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events.

本新聞稿包含適用的加拿大證券立法所指的 “前瞻性信息”。這些陳述與未來的事件或未來的表現有關。使用任何 “可能”、“打算”、“期望”、“相信”、“將”、“預計”、“估計” 以及與非歷史事實的事項相關的類似表達方式和陳述均旨在識別前瞻性信息,並基於公司當前對此類未來事件的結果和時機的看法或假設。

The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company's performance, business objectives and milestones and the anticipated timing thereof, and costs in connection with, the execution or achievement of such objectives and milestones, including its plans to continue seeking legal opportunities to increase responsible access to natural psilocybin around the world and PharmAla's development and distribution of the Company's psilocybin; the Company and the Company's partners to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the expectations with respect to the Company's latest Health Canada approved psilocybin import; the Company's continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's commitment to making further announcements with respect to its overall R&D project, including its partnership with PharmAla and the research project to develop a process for the commercial manufacture of natural-source Active Pharmaceutical Ingredient (API) derived from the Company's psilocybin truffles; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; and The Company's ability to extract and expand access to psilocybin products.

此處包含的前瞻性信息和前瞻性陳述包括但不限於以下方面的陳述:公司的業績、業務目標和里程碑及其預期時間,以及與執行或實現這些目標和里程碑相關的成本,包括其繼續尋求法律機會以增加全球範圍內自然迷幻藥獲取渠道的計劃以及PharMala對公司迷幻藥的開發和分銷;公司和公司的合作伙伴維持其規定的許可證並獲得公司執行上述計劃所需的所有必要額外許可證和監管部門的批准;對公司最近批准的迷幻藥進口的預期;公司繼續承諾確保合法、負責任地獲得Red Light的標準化天然迷幻藥產品;公司承諾進一步宣佈其整體研發項目,包括與PharMala的合作以及開發的研究項目一個源自公司迷幻藥松露的天然活性藥物成分(API)的商業生產流程;公司證明了迷幻藥的潛在治療益處;公司從天然存在的迷幻藥松露中獲得重要見解;以及公司提取和擴大迷幻藥產品准入的能力。

Forward-Looking information in this press release are based on certain assumptions and expected future events, namely: the Company's ability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' abilities, including PharmAla and CCrest Laboratories, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's ability to realize its plans for its latest Health Canada approved psilocybin import; the Company's ability for its continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's ability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with PharmAla and their research project to develop a process for the commercial manufacture of natural-source Active Pharmaceutical Ingredient (API) derived from the Company's psilocybin truffles; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; and the ability to extract and expand access to psilocybin products.

本新聞稿中的前瞻性信息基於某些假設和預期的未來事件,即:公司維持或超過其當前業績、實現其業務目標和里程碑的能力,以及在與執行或實現這些目標和里程碑相關的預期時間和成本下的能力;公司和公司的合作伙伴,包括PharMala和CCREST Laboratories,維持其規定許可證並獲得所有必要的額外許可和監管部門批准的能力要求公司按上述方式執行其計劃;公司實現其最近批准的迷幻藥進口計劃的能力;公司繼續承諾確保合法、負責任地獲得Red Light的標準化天然迷幻藥產品的能力;公司有能力兌現其就其總體研發項目發佈進一步公告的承諾,包括與PharMala的合作以及開發商業工藝的研究項目天然產品的製造-採購源自公司迷幻藥松露的活性藥物成分(API);公司證明了迷幻藥的潛在治療益處;公司從天然存在的迷幻藥松露中獲得了重要見解;以及提取和擴大迷幻藥產品准入的能力。

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company's inability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' inabilities, including PharmAla and CCrest Laboratories, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's inability to realize upon its plans for its latest Health Canada approved psilocybin import; the Company's inability to maintain its commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's inability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with PharmAla; and The Company's ability to expand and extract access to psilocybin products.

這些陳述涉及已知和未知的風險、不確定性和其他因素,可能導致實際業績、業績或成就與此類聲明所表達或暗示的結果存在重大差異,包括但不限於:公司無法維持或超過其當前業績,無法實現其業務目標和里程碑,在預期的時間和成本下無法執行或實現這些目標和里程碑;公司和公司合作伙伴的無能,包括 PharPhar的資格馬拉和CCrest Laboratories將維持其規定的許可證,並獲得公司執行上述計劃所需的所有必要額外許可證和監管部門的批准;公司無法實現其最近批准的加拿大衛生部批准的迷幻藥進口計劃;公司無法兌現其承諾,確保合法、負責任地獲得紅光的標準化天然迷幻藥產品;公司無法兌現其就其總體情況發佈進一步公告的承諾研發項目,包括與PharMala的合作伙伴關係;以及該公司擴大和提取迷幻藥產品准入的能力。

The Company cannot make medical claims and is purely in a R&D phase with its partners CCrest Labs and PharmAla Biotech Holdings inc.

該公司無法提出醫療索賠,其合作伙伴CCrest Labs和PharMala Biotech Holdings inc純粹處於研發階段。

Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

進一步提醒讀者不要過分依賴前瞻性陳述,因爲無法保證前瞻性陳述所依據的計劃、意圖或預期會實現。儘管管理層在編寫時認爲此類信息是合理的,但可能被證明是不正確的,實際結果可能與預期的結果存在重大差異。

Forward-Looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

本新聞稿中包含的前瞻性陳述受本警示聲明的明確限制,反映了公司截至本文發佈之日的預期,此後可能會發生變化。除非適用法律要求,否則公司沒有義務更新或修改任何前瞻性陳述,無論是由於新信息、估計或觀點、未來事件或結果還是其他原因,也沒有義務解釋後續實際事件與此類前瞻性信息之間的任何重大差異。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論